



Final Appraisal Recommendation

Advice No: 2214 – July 2014

Aripiprazole (Abilify Maintena®) 400 mg powder and solvent for prolonged release suspension for injection

Submission by Otsuka Pharmaceuticals (UK) Ltd and Lundbeck Ltd

Recommendation of AWMSG

Aripiprazole (Abilify Maintena®) 400 mg powder and solvent for prolonged release suspension for injection is recommended as an option for use within NHS Wales for the maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 909), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Otsuka Pharmaceuticals (UK) Ltd and Lundbeck Ltd
Date of first issue	July 2014
Last reviewed	September 2017

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2214: Aripiprazole (Abilify Maintena®) 400 mg powder and solvent for prolonged release suspension for injection. July 2014.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.